Ulcerative colitis is one of the most prevalent gastroenterological diseases, whose etiology and pathogenesis still remain not fully elucidated and treatment is often insufficiently effective. Ulcerative colitis is accompanied by the damage not only of the large intestine but also extracolonic complications, such as activation of immune disorders, changes of the functional activity of hepato-biliary system organs. Due to modern thoughts, the main pathogenetic mechanisms of pathologic process formation in ulcerative colitis are associated with disbalance in the system of lipid peroxidation – antioxidant defense.

Regulation of lipoperoxidation is performed by multistage system of antioxidant defense, which includes specialized enzymatic and non-enzymatic antioxidants. That is why the investigation of the preparations, which are the inhibitors of the proinflammatory enzymes, causing activation and increased content of proinflammatory processes mediators, changing the oxidative homeostasis in hepato-biliary zone is very actual. Such inhibitors include celecoxib – highly selective cyclooxygenase-2 inhibitor and darbufelone – nonsteroidal anti-inflammatory drug of dual action, capable of inhibiting both cyclooxygenase-2 (COX) and 5-lipoxygenase. Darbufelone was created with the aim to achieve the anti-inflammatory effect and to avoid the side effects of the latter, first of all their negative influence on gastrointestinal tract and cardio-vascular system.

It was shown that in experimental acetic colitis functioning of the enzymatic and nonenzymatic pathways of the antioxidant defense system are inhibited. Revealed changes in liver in experimental colitis indicate the involvement of other digestive system organs in this pathological process. It was shown that the use of proinflammatory enzymes is accompanied by the increased activity of antioxidant enzymes and increase of the content of natural antioxidants, which favors normalization of the oxidative-reductive processes and inhibition of the pathological process. It was shown that the use of COX-2 inhibitor celecoxib was more efficient than the use of dual COX-2/5-LOX inhibitor darbufelone, indicating the better anti-inflammatory effect of celecoxib, despite its possible side effects, and the viability of the use of this blocker in antioxidant therapy in the treatment of ulcerative colitis.

Keywords: acetic colitis, proinflammatory enzymes, inhibitors (celecoxib, darbufelone), ascorbic acid, glutathione system

Full text: PDF (Ukr) 182K